product name Halobetasol Propionate
Description: Halobetasol Propionate (also known as halobetasol, BMY-30056, and CGP-14458) is an anti-inflammatory and a dermatologic agent commonly used to treat psoriasis. Ulobetasol is a corticosteroid. It is a group I corticosteroid under the US classification, the most potent class of such drugs. Halobetasol propionate is usually supplied as a 0.05% topical cream.
References: Indian J Dermatol Venereol Leprol. 2009 Mar-Apr;75(2):186-7; Am J Clin Dermatol. 2005;6(5):311-6.
484.96
Formula
C25H31ClF2O5
CAS No.
66852-54-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 97 mg/mL (200.0 mM)
Water: <1 mg/mL
Ethanol: 38 mg/mL (78.4 mM)
Solubility (In vivo)
Synonyms
BMY-30056, CGP-14458
other peoduct :
| In Vitro |
In vitro activity: Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Indian J Dermatol Venereol Leprol. 2009 Mar-Apr;75(2):186-7; Am J Clin Dermatol. 2005;6(5):311-6. |
